Retifanlimab Under FDA Priority Review for Advanced Anal Canal Cancer
News
Retifanlimab is under review in the U.S. as a treatment for advanced squamous cell carcinoma of the anal canal (SCAC), a rare cancer of the digestive system, in adults ... Read more